Zeltiq Aesthetics (NASDAQ: ZLTQ) and PerkinElmer (NYSE:PKI) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Institutional and Insider Ownership

91.7% of PerkinElmer shares are owned by institutional investors. 15.6% of Zeltiq Aesthetics shares are owned by insiders. Comparatively, 2.2% of PerkinElmer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Zeltiq Aesthetics and PerkinElmer’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zeltiq Aesthetics N/A N/A N/A ($0.03) -1,882.67
PerkinElmer $2.12 billion 3.81 $234.29 million $2.21 33.11

PerkinElmer has higher revenue and earnings than Zeltiq Aesthetics. Zeltiq Aesthetics is trading at a lower price-to-earnings ratio than PerkinElmer, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Zeltiq Aesthetics and PerkinElmer, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zeltiq Aesthetics 0 8 1 0 2.11
PerkinElmer 2 8 5 0 2.20

Zeltiq Aesthetics currently has a consensus target price of $56.83, indicating a potential upside of 0.63%. PerkinElmer has a consensus target price of $68.23, indicating a potential downside of 6.76%. Given Zeltiq Aesthetics’ higher possible upside, analysts clearly believe Zeltiq Aesthetics is more favorable than PerkinElmer.

Profitability

This table compares Zeltiq Aesthetics and PerkinElmer’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zeltiq Aesthetics 9.78% 31.74% 20.11%
PerkinElmer 18.27% 13.11% 6.82%

Dividends

PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. Zeltiq Aesthetics does not pay a dividend. PerkinElmer pays out 12.7% of its earnings in the form of a dividend.

Summary

PerkinElmer beats Zeltiq Aesthetics on 7 of the 12 factors compared between the two stocks.

Zeltiq Aesthetics Company Profile

ZELTIQ Aesthetics, Inc. is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians. It also offers consumables, which are CoolSculpting procedure packs that are needed to perform procedures using its CoolSculpting system. CoolSculpting is a non-invasive fat reduction procedure. CoolSculpting utilizes its controlled cooling technology to selectively reduce stubborn fat bulges. The CoolSculpting system includes CoolSculpting control unit and CoolSculpting applicators. The CoolSculpting Applicator delivers vacuum suction and cooling to the fat bulge being treated.

PerkinElmer Company Profile

PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.

Receive News & Ratings for Zeltiq Aesthetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.